Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation.
about
Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Proteomics profiling of CLL ve ...... of spliceosome dysregulation.
@en
Proteomics profiling of CLL ve ...... of spliceosome dysregulation.
@nl
type
label
Proteomics profiling of CLL ve ...... of spliceosome dysregulation.
@en
Proteomics profiling of CLL ve ...... of spliceosome dysregulation.
@nl
prefLabel
Proteomics profiling of CLL ve ...... of spliceosome dysregulation.
@en
Proteomics profiling of CLL ve ...... of spliceosome dysregulation.
@nl
P2093
P2860
P50
P356
P1476
Proteomics profiling of CLL ve ...... of spliceosome dysregulation.
@en
P2093
Andrew J Steele
David Oscier
James Clarke
Jonathan C Strefford
Marta Larrayoz
Matthew J Carter
Renata Walewska
P2860
P304
P356
10.1074/MCP.RA117.000539
P577
2018-01-24T00:00:00Z